Natera, Inc. ($NTRA) Stock Forecast: Up 6.8% Today

What is Natera, Inc.?

Natera (NTRA) is a global leader in cell-free DNA testing with a market capitalization of $12.57 billion. The stock had a strong bullish movement today.

Why is Natera, Inc. going up?

NTRA stock is up 6.8% on Aug 9, 2024 13:47

• Natera reported a Q2 loss but surpassed revenue estimates, indicating strong performance and potential growth prospects.
• The stock has outperformed the market over the past 5 years, showcasing consistent growth and investor confidence.
• Participation in the Canaccord Genuity 44th Annual Growth Conference suggests Natera's commitment to showcasing its strategies and growth prospects, which might have positively influenced investor sentiment.
• Overall, the combination of positive financial results, long-term market outperformance, and active participation in industry events likely contributed to the bullish movement in Natera's stock today.

NTRA Price Chart

NTRA News

Natera ( NTRA ) Reports Q2 Loss, Tops Revenue Estimates

Natera (NTRA) delivered earnings and revenue surprises of 56.52% and 21.54%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

https://www.zacks.com/stock/news/2319622/natera-ntra-reports-q2-loss-tops-revenue-estimates

$100 Invested In Natera 5 Years Ago Would Be Worth This Much Today - Natera ( NASDAQ:NTRA )

Natera NTRA has outperformed the market over the past 5 years by 15.56% on an annualized basis producing an average annual return of 28.41%. Currently, Natera has a market capitalization of $12.57 billion.

https://www.benzinga.com/insights/news/24/08/40199311/100-invested-in-natera-5-years-ago-would-be-worth-this-much-today

Natera to Participate in the Canaccord Genuity 44th Annual Growth Conference

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced that members of its leadership team will present at the Canaccord Genuity 44th Annual Growth Conference on Wednesday, Aug. 14 at 12:30 pm ET | 9:30 am PT in Boston, MA. A live webcast and audio archive of the event may be accessed through the investor relations section of the Natera website at investor.natera.com. Jetzt den vollständigen Artikel lesen

https://www.wallstreet-online.de/nachricht/18349572-natera-to-participate-the-canaccord-genuity-44th-annual-growth-conference

Natera to Participate in the Canaccord Genuity 44th Annual Growth Conference | NTRA Stock News

Natera to present at Canaccord Genuity Growth Conference on Aug 14. Learn about the cell-free DNA testing leader''s strategies and growth prospects. Live webcast available for investors.

https://www.stocktitan.net/news/NTRA/natera-to-participate-in-the-canaccord-genuity-44th-annual-growth-r8fltqjczgac.html

Trending Today

Novo Nordisk A/S ($NVO) Stock Forecast: Down 5.1% Today

Lennar Corporation Class A ($LEN) Stock Forecast: Down 5.2% Today

Bittensor ($TAO) Crypto Forecast: Up 9.4% Today

Aptos ($APT) Crypto Forecast: Up 6.6% Today

Sui ($SUI) Crypto Forecast: Up 11.4% Today

Intel Corporation ($INTC) Stock Forecast: Up 5.6% Today

Bumble Inc. ($BMBL) Stock Forecast: Down 5.4% Today

Fetch.ai ($FET) Crypto Forecast: Up 5.1% Today

FedEx Corporation ($FDX) Stock Forecast: Down 14.5% Today

Nike Inc. ($NKE) Stock Forecast: Up 6.2% Today

Natera, Inc. Price History

19.06.2024 - NTRA Stock was down 5.1%

• The CEO selling over $600k in company stock might have signaled a lack of confidence in the company's future prospects, leading to a bearish sentiment among investors.
• Despite Natera's strong historical performance outperforming the market over the past 5 years, the recent insider selling could have eroded investor trust in the company's growth potential.
• The market may be reacting negatively to the CEO's decision to offload a substantial amount of company stock, causing a sell-off and driving the stock price down significantly today.

05.05.2024 - NTRA Stock was up 5.2%

• Natera (NTRA) saw a strong bullish movement in the market recently.
• This positive trend is linked to Natera's upgraded initial 2024 guidance in Q1, pointing towards promising growth opportunities ahead.
• Some initial market uncertainty arose from the selling of shares by directors Gail Marcus and Rowan Chapman. However, the overall positive market outlook and raised guidance overshadowed these concerns.
• The decrease in short interest in Natera also played a role in the upward movement, reflecting a decline in bearish sentiment among investors.

10.04.2024 - NTRA Stock was up 11.9%

• Natera's stock reached a three-year peak post strong first-quarter earnings that exceeded market forecasts.
• The market's upbeat attitude towards Natera may stem from the increasing importance of genomics in healthcare, with Natera leading the way in uncovering genetic insights for better health outcomes.
• Natera's stock rally could also be linked to the general market optimism, as seen with other genomics companies posting significant gains.
• Investors are eyeing Natera for its strong performance and growth prospects in the expanding genomics market, expected to see substantial growth by 2033.

25.03.2024 - NTRA Stock was down 5.1%

• StockNews.com downgraded the stock to a sell rating, potentially influencing investor sentiment negatively.
• Natera's chief legal officer engaged in stock transactions, while the company's CFO and president of clinical diagnostics sold company stock, which may have impacted the bearish movement.
• The market's view of Natera might have been influenced by insider selling activities, leading to a decline in the stock price.
• Despite promising developments in the oncology market, internal selling within Natera appears to have outweighed positive aspects, resulting in the stock's bearish movement.

19.03.2024 - NTRA Stock was down 6.8%

• The bearish movement in Natera Inc's stock today could be related to significant insider selling activity by both the CEO and President. This might have raised concerns among investors about the company's future prospects.
• The president sold over $7.2 million in company stock, and the CEO sold shares worth over $630k. This could suggest a lack of confidence in the company's performance or potential challenges ahead.
• Such high levels of insider selling may have unsettled investors, causing a sell-off in the stock as they followed suit to reduce potential losses or risks associated with insider actions.
• Investors might view these insider sales as a lack of alignment between company leadership and shareholders, leading to a negative sentiment and resulting in the bearish movement of Natera Inc's stock.

10.04.2024 - NTRA Stock was up 12.3%

• Natera's stock saw a strong bullish movement today, rising significantly in pre-market trading.
• The surge in Natera's stock price can be attributed to the company's strong first-quarter earnings report, where they outperformed market expectations with a lower-than-expected GAAP loss per share and higher-than-anticipated quarterly sales.
• The positive earnings report showcases Natera's continued growth and success in the genomics industry, positioning them as a key player in unlocking the potential of genetic testing and personalized medicine.
• The revelation of Natera's CFO selling over $175k in company stock might have raised some eyebrows, but it did not seem to deter investors who were impressed by the company's financial performance and growth prospects.

23.03.2024 - NTRA Stock was up 5.2%

• The bullish movement in NTRA stock today can be attributed to the positive market sentiment surrounding the company's groundbreaking technology and its recent milestone of over 200 peer-reviewed publications.
• The strong focus on scientific rigor and real-world clinical evidence showcased in these publications has likely boosted investor confidence in Natera's ability to improve patient outcomes, driving up the stock price.
• Despite reports of insider selling by the CEO and President, the overall market seems to be more influenced by the company's scientific achievements and potential for growth in the genetic testing industry.
• Investors may view the insider selling as a routine profit-taking activity rather than a signal of underlying issues within the company, further supporting the bullish trend in NTRA stock.

18.06.2024 - NTRA Stock was down 5.2%

• The bearish movement in Natera's stock could be attributed to the CEO selling over $600k in company stock.
• Investors may interpret the CEO's decision to sell a substantial amount of company stock as a lack of faith in the company's potential for growth or profitability in the near term.
• The market's reaction to the CEO's stock sale could indicate a loss of confidence among investors leading to a sell-off of Natera's shares and contributing to the bearish movement in the stock price today.

30.06.2024 - NTRA Stock was down 5.2%

• The bearish movement in NTRA stock could be attributed to the CFO and the president of clinical diagnostics selling significant amounts of company shares, possibly raising concerns among investors about the company's future performance.
• Despite the positive news about the validation of Natera's Signatera test for Merkel Cell Carcinoma, the focus on insider selling might have overshadowed the positive developments in the company.
• Investors might be cautious about the upcoming earnings report, even though Natera is expected to beat earnings estimates. The uncertainty surrounding the stock could have led to profit-taking and contributed to the bearish movement.
• The market might be reacting to the overall selling pressure from company insiders, leading to a negative sentiment towards Natera's stock despite the promising clinical utility of their products.

06.07.2024 - NTRA Stock was up 5.5%

• Participation in a growth conference likely sparked investor interest and confidence in the company's future prospects.
• A presentation by the leadership team may have highlighted innovative strategies and growth opportunities, leading to increased optimism among investors.
• The availability of a live webcast could have provided further insights into advancements in cell-free DNA testing, potentially attracting more attention from the investment community.

07.07.2024 - NTRA Stock was up 6.3%

• Natera has outperformed the market significantly over the past 5 years, showcasing strong growth prospects and investor confidence.
• The company's participation in the Canaccord Genuity 44th Annual Growth Conference likely generated positive investor sentiment and highlighted Natera's strategic initiatives and future growth prospects.
• The live webcast of the event provided investors with an opportunity to gain insights into Natera's advancements in cell-free DNA testing, potentially driving further interest and investment in the company.

09.07.2024 - NTRA Stock was up 6.8%

• Natera reported a Q2 loss but surpassed revenue estimates, indicating strong performance and potential growth prospects.
• The stock has outperformed the market over the past 5 years, showcasing consistent growth and investor confidence.
• Participation in the Canaccord Genuity 44th Annual Growth Conference suggests Natera's commitment to showcasing its strategies and growth prospects, which might have positively influenced investor sentiment.
• Overall, the combination of positive financial results, long-term market outperformance, and active participation in industry events likely contributed to the bullish movement in Natera's stock today.